Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Spasm Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
48
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 21, 2026, 3:41 PM EDT
Completed No phase listed Observational

Diagnostic Evaluation of Patients With Neuromuscular Disease

NCT00015470
View directory record Official record
Conditions
Neuromuscular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 4 Interventional Results available

Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention

NCT02832115
View directory record Official record
Conditions
Radial Artery Spasm, Angina, Coronary Artery Disease
Interventions
Topical Nitroglycerine, Topical Lidocaine
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Early Phase 1 Interventional

Treatment of Muscle Cramps in Patients With Liver Cirrhosis

NCT01495403
View directory record Official record
Conditions
Liver Cirrhosis, Muscle Cramps
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 21, 2026, 3:41 PM EDT
Recruiting Phase 4 Interventional

Magnesium and Cramping

NCT06745388
View directory record Official record
Conditions
Uterine Cramps, Postoperative Pain Management, Hysteroscopy
Interventions
Magnesium sulfate, Ketamine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Pau d' Arco in Primary Dysmenorrhea

NCT04245540
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
Pau d' Arco
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test

NCT05489081
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Not applicable Interventional

Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial

NCT04650295
View directory record Official record
Conditions
Cirrhosis, Muscle Cramp, Ascites
Interventions
Household Remedy, Tap water
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jul 21, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure

NCT06080438
View directory record Official record
Conditions
Tears; Excess, Eyelid Spasm
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

NCT00609063
View directory record Official record
Conditions
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

NCT00890162
View directory record Official record
Conditions
Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions
Epinephrine, Omalizumab (Xolair), Placebos
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soluble Corn Fiber and Calcium Utilization in Adolescents

NCT01571440
View directory record Official record
Conditions
Osteoporosis
Interventions
No soluble corn fiber, 12 g soluble corn fiber
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
12 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Amlodipine Plus Botulinum Toxin for Focal Dystonia

NCT00015457
View directory record Official record
Conditions
Focal Dystonia
Interventions
Amlodipine plus Botulinum toxin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2013 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm

NCT04671082
View directory record Official record
Conditions
Back Muscle Spasm, Back Pain, Back Strain, Back Spasm Upper, Muscle Spasm, Acute Pain
Interventions
Tolperisone Hydrochloride, Placebo
Drug
Lead sponsor
Neurana Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Surprise, Arizona • Little Rock, Arkansas • Canoga Park, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 21, 2026, 3:41 PM EDT
Recruiting Phase 2 Interventional

A Study to Prevent Infantile Spasms Relapse

NCT06819670
View directory record Official record
Conditions
Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
Interventions
Prednisolone, Famotidine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Months to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jul 21, 2026, 3:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 21, 2026, 3:41 PM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 21, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional Results available

Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms

NCT02865395
View directory record Official record
Conditions
Overactive Bladder
Interventions
Belladonna and Opium Suppository, Rectal Exam
Drug · Procedure
Lead sponsor
Campbell Grant
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

NCT01678209
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 21, 2026, 3:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Topical Radial Artery Vasodilation

NCT01155167
View directory record Official record
Conditions
Cardiac Catheterization, Spasm
Interventions
Nitroglycerin and lidocaine, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 21, 2026, 3:41 PM EDT
Terminated Phase 2 Interventional

Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)

NCT00514202
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Placebo, Dextroamphetamine SR
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 21, 2026, 3:41 PM EDT
Recruiting Phase 4 Interventional

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

NCT06195241
View directory record Official record
Conditions
Benign Essential Blepharospasm, Hemifacial Spasm
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 3:41 PM EDT